IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.62
+3.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -18.3%
- EBIT
- -18.6%
- EPS
- +1.1%
- Free cash flow
- +0.8%
- Operating cash flow
- +0.7%
Forward estimates
Based on analyst estimates
- Revenue
- +402.9%
- EBITDA
- -11.5%
- EPS
- -3.7%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.4%
- EBIT
- -21.6%
- Net income
- -22.2%
- EPS
- -1.5%
- Free cash flow
- -8.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026